Dr Carbone talks with ecancer at the Best of ASCO 2017 meeting in Miami about the developments of targeted therapies for EGFR and ALK mutations in advanced lung cancer patients. He goes on to discuss the new drugs that have been yielding improved efficacy...
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2uIh30w
via IFTTT
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου